StriVectin still French favorite
This article was originally published in The Rose Sheet
Executive Summary
For the second time in less than a year, StriVectin-SD - the "stretch-mark cream turned anti-wrinkle phenomenon" - has been selected by French consumers as the No. 1 skin cream, according to a June 25 release. At the 17 annual "Grand Prix of Beauty," held in Paris by French beauty magazine Advantages, StriVectin-SD was named the favorite of 5,000 women across France - based on pleasure, innovation, confidence in the brand and effectiveness - "much to the chagrin of an audience comprised of French cosmetic giants the likes of Lancôme, ReVive, La Mer, L'Oréal, Yves Rocher and many others," Salt Lake City-based Klein-Becker says. Formerly, the cream was rated best by 264 women polled by France's leading consumer magazine, 60 Millions De Consommateur (1"The Rose Sheet" Oct. 16, 2006, In Brief)...
You may also be interested in...
StriVectin in France
Anti-wrinkle cream StriVectin-SD was rated the "best, most effective" anti-wrinkle face cream in a poll of 264 French women, according to France's leading consumer magazine, 60 Millions De Consommateur, Klein-Becker says. The women, who ranged in age from 30-70, chose StriVectin over 11 "famous formulations" by Dior,Chanel,ROC,L'Oréal, Lancôme and other high-end products, most of which are made in France, company says. Klein-Becker notes it was surprised by the results since French women are "extremely skeptical about products from America." StriVectin launched in Paris in August 2004 in the Sephora flagship store located on the Champs-Elysées...
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.